{"id":"W4206953274","doi":"10.1016/j.annonc.2021.08.062","title":"666P Pembrolizumab (pembro) monotherapy as first-line therapy in advanced clear cell renal cell carcinoma (ccRCC): Results after a minimum of 41 months of follow-up from KEYNOTE-427 cohort A","year":2021,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre","funders":"National Cancer Institute; Foundation Medicine; Genentech; Ipsen; Congressionally Directed Medical Research Programs; Celldex Therapeutics; Gateway for Cancer Research; Calithera Biosciences; Astellas Pharma; Eisai; U.S. Department of Defense; Exelixis; GlaxoSmithKline; AstraZeneca; Bristol-Myers Squibb; Pfizer","keywords":"Medicine; Pembrolizumab; Cohort; Clear cell renal cell carcinoma; Renal cell carcinoma; Oncology; Internal medicine; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0008785311,0.0004172607,0.0006262008,0.0003414333,0.0004404148,0.0008078334,0.000469618,0.0003996933,0.002590776],"category_scores_gemma":[0.001124215,0.0002502256,0.000951848,0.0004872258,0.0001939803,0.0006205666,0.0004732479,0.0007644526,0.0009773429],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007220735,"about_ca_system_score_gemma":0.0009550637,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.007166642,"about_ca_topic_score_gemma":0.01127454,"domain_scores_codex":[0.9995692,0.00008008282,0.00002442721,0.0001351523,0.00008838833,0.0001026257],"domain_scores_gemma":[0.9992839,0.00009077105,0.0001690709,0.0001309795,0.0001312398,0.0001941699],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.1196233,0.006295907,0.7382231,0.0005162565,0.003850289,0.0004678063,0.0003917258,0.002173416,0.01328134,0.0002068467,0.02598183,0.08898831],"study_design_scores_gemma":[0.006355426,0.009695333,0.972635,0.00005243194,0.001289778,0.0004016236,0.0002185917,0.0007331285,0.0016928,0.0001252922,0.006763674,0.00003695376],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9761445,0.0006265698,0.0001954449,0.0001614996,0.00004450783,0.000187881,0.02070961,0.00003720559,0.001892824],"genre_scores_gemma":[0.9374531,0.0008097025,0.000493542,0.000354526,0.00008692508,0.0002936232,0.05605956,0.00004110367,0.004407874],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.007166642,"threshold_uncertainty_score":0.01424986,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.03871733226255215,"score_gpt":0.3150274137416387,"score_spread":0.2763100814790866,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}